Literature DB >> 22750848

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Giannicola Genovese1, Ayla Ergun, Sachet A Shukla, Benito Campos, Jason Hanna, Papia Ghosh, Steven N Quayle, Kunal Rai, Simona Colla, Haoqiang Ying, Chang-Jiun Wu, Sharmistha Sarkar, Yonghong Xiao, Jianhua Zhang, Hailei Zhang, Lawrence Kwong, Katherine Dunn, Wolf Ruprecht Wiedemeyer, Cameron Brennan, Hongwu Zheng, David L Rimm, James J Collins, Lynda Chin.   

Abstract

UNLABELLED: Leveraging The Cancer Genome Atlas (TCGA) multidimensional data in glioblastoma, we inferred the putative regulatory network between microRNA and mRNA using the Context Likelihood of Relatedness modeling algorithm. Interrogation of the network in context of defined molecular subtypes identified 8 microRNAs with a strong discriminatory potential between proneural and mesenchymal subtypes. Integrative in silico analyses, a functional genetic screen, and experimental validation identified miR-34a as a tumor suppressor in proneural subtype glioblastoma. Mechanistically, in addition to its direct regulation of platelet-derived growth factor receptor-alpha (PDGFRA), promoter enrichment analysis of context likelihood of relatedness-inferred mRNA nodes established miR-34a as a novel regulator of a SMAD4 transcriptional network. Clinically, miR-34a expression level is shown to be prognostic, where miR-34a low-expressing glioblastomas exhibited better overall survival. This work illustrates the potential of comprehensive multidimensional cancer genomic data combined with computational and experimental models in enabling mechanistic exploration of relationships among different genetic elements across the genome space in cancer. SIGNIFICANCE: We illustrate here that network modeling of complex multidimensional cancer genomic data can generate a framework in which to explore the biology of cancers, leading to discovery of new pathogenetic insights as well as potential prognostic biomarkers. Specifically in glioblastoma, within the context of the global network, promoter enrichment analysis of network edges uncovered a novel regulation of TGF-β signaling via a Smad4 transcriptomic network by miR-34a.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750848      PMCID: PMC3911772          DOI: 10.1158/2159-8290.CD-12-0111

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  48 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

2.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

Review 3.  TGFbeta signalling: a complex web in cancer progression.

Authors:  Hiroaki Ikushima; Kohei Miyazono
Journal:  Nat Rev Cancer       Date:  2010-06       Impact factor: 60.716

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Authors:  Yunqing Li; Fadila Guessous; Ying Zhang; Charles Dipierro; Benjamin Kefas; Elizabeth Johnson; Lukasz Marcinkiewicz; Jinmai Jiang; Yanzhi Yang; Thomas D Schmittgen; Beatriz Lopes; David Schiff; Benjamin Purow; Roger Abounader
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

6.  p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.

Authors:  N R Christoffersen; R Shalgi; L B Frankel; E Leucci; M Lees; M Klausen; Y Pilpel; F C Nielsen; M Oren; A H Lund
Journal:  Cell Death Differ       Date:  2009-08-21       Impact factor: 15.828

7.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Kati Maharry; Yue-Zhong Wu; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Kelsi B Holland; Susan P Whitman; Heiko Becker; Sebastian Schwind; Klaus H Metzeler; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 50.717

8.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

9.  Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.

Authors:  Cameron Brennan; Hiroyuki Momota; Dolores Hambardzumyan; Tatsuya Ozawa; Adesh Tandon; Alicia Pedraza; Eric Holland
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  The transcriptional network for mesenchymal transformation of brain tumours.

Authors:  Maria Stella Carro; Wei Keat Lim; Mariano Javier Alvarez; Robert J Bollo; Xudong Zhao; Evan Y Snyder; Erik P Sulman; Sandrine L Anne; Fiona Doetsch; Howard Colman; Anna Lasorella; Ken Aldape; Andrea Califano; Antonio Iavarone
Journal:  Nature       Date:  2009-12-23       Impact factor: 49.962

View more
  60 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

2.  The RNA-binding protein SART3 promotes miR-34a biogenesis and G1 cell cycle arrest in lung cancer cells.

Authors:  Emily J Sherman; Dylan C Mitchell; Amanda L Garner
Journal:  J Biol Chem       Date:  2019-10-16       Impact factor: 5.157

Review 3.  Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs.

Authors:  Desiree Floyd; Benjamin Purow
Journal:  Neuro Oncol       Date:  2014-04-10       Impact factor: 12.300

4.  Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.

Authors:  Jin-Ah Kim; Meenakshi Anurag; Jamunarani Veeraraghavan; Rachel Schiff; Kaiyi Li; Xiao-Song Wang
Journal:  Mol Cancer Res       Date:  2016-08-03       Impact factor: 5.852

5.  Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III.

Authors:  Michela Visani; Dario de Biase; Gianluca Marucci; Serenella Cerasoli; Evandro Nigrisoli; Maria Letizia Bacchi Reggiani; Fiorenzo Albani; Agostino Baruzzi; Annalisa Pession
Journal:  Mol Oncol       Date:  2013-12-24       Impact factor: 6.603

6.  MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell.

Authors:  Ke Liu; Jun Huang; Min Xie; Yan Yu; Shan Zhu; Rui Kang; Lizhi Cao; Daolin Tang; Xuanchu Duan
Journal:  Autophagy       Date:  2014-01-03       Impact factor: 16.016

7.  MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.

Authors:  Mónica Rivera-Díaz; Miguel A Miranda-Román; Daniel Soto; Mario Quintero-Aguilo; Humberto Ortiz-Zuazaga; María J Marcos-Martinez; Pablo E Vivas-Mejía
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 8.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

9.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Authors:  Josie Hayes; Helene Thygesen; Charlotte Tumilson; Alastair Droop; Marjorie Boissinot; Thomas A Hughes; David Westhead; Jane E Alder; Lisa Shaw; Susan C Short; Sean E Lawler
Journal:  Mol Oncol       Date:  2014-11-28       Impact factor: 6.603

10.  Expression level of human miR-34a correlates with glioma grade and prognosis.

Authors:  Haifeng Gao; Hongyang Zhao; Wei Xiang
Journal:  J Neurooncol       Date:  2013-03-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.